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Abstract
Rational Chronic obstructive pulmonary disease (COPD) impairs lung function and induces systemic effects, resulting in impaired
quality of life. Skeletal muscle dysfunction—characteristic of advanced COPD patients—limits a patient’s ability to perform activities
of daily living (ADL). In addition, dysphagia is commonly observed in COPD patients.
Patient concern This case report documents a 42-year-old man with very severe COPD. He experienced aggravation of the
symptoms during standard medical treatment and his ability to perform the ADL was signiﬁcantly impaired. Furthermore, his
dysphagia worsened despite oromotor training.
Diagnosis He was diagnosed as very severe COPD have a problem with swallowing and respiratory function.
Intervention Upon NIPPV treatment, the patient’s ability to perform the ADL, as well as his dysphagia, showed improvement.
Outcomes Thus, we report the remarkable improvement of physical function, as well as dysphagia, in a very severe COPD patient
after NIPPV treatment.
Lessons NIPPV may be useful as a treatment option for such patients.
Abbreviations: 6MWT = 6-minute walking test, ADL = activities of daily living, BFI = Brief Fatigue Inventory, COPD = chronic
obstructive pulmonary disease, FIM = Functional Independence measure, HRQOL = health-related quality of life, LCADL = London
Chest Activity of Daily Living, MFIS =Modiﬁed Fatigue Impact Scale, NIPPV = noninvasive positive pressure ventilation, UES = upper
esophageal sphincter, VFSS = videoﬂuoroscopic swallowing study.
Keywords: activities of daily living, chronic obstructive pulmonary disease, intermittent positive-pressure ventilation, noninvasive
ventilation, respiratory function testsEditor: N/A.
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11. Introduction
Chronic obstructive pulmonary disease (COPD) is known to
induce—in addition to respiratory symptoms—a decrease in
muscle strength and endurance caused by systematic effects, as
well as vulnerability to fatigue, and a decline in exercise capacity
and swallowing function.[1,2] A decrease in physical activities,
and the resulting sedentary lifestyle, further exacerbate the
weakened pulmonary function, resulting in a vicious cycle that
leads to the decline of health-related quality of life (HRQOL) and
physical ability at a rate that is disproportionate to the decline of
the lung function. COPD is not simply a lung disorder; COPD-
related mortality is associated with deterioration in a patient’s
overall physical function. [3]
In acute exacerbation of COPD, noninvasive positive pressure
ventilation (NIPPV) is known to improve related symptoms and
to reduce the length of hospital stay, as well as intubation rate and
mortality rate.[4] If NIPPV is utilized as adjunct treatment for
severe COPD patients, modest improvement in exercise perfor-
mance may be expected; however, the level of evidence
supporting this is low and it remains categorized as a weak
recommendation.[5]
This case report seeks to document a dramatic improvement in
various physical functions, as observed in a GOLD criteria stage
Table 1
Comparison of various parameters before and after application of
NIPPV.
Before NIPPV
(November 22, 2016)
After NIPPV
(February 28, 2017)
Jung et al. Medicine (2018) 97:43 MedicineIV (very severe) COPD patient after nocturnal NIPPV treatment.
Moreover, this is the ﬁrst report on the improvement of
swallowing function upon nocturnal NIPPV treatment. Patient
had provided informed consent for the case report and agreed
publishing.Pulmonary function test
FVC 1090mL (22%) 1430mL (29%)
FEV1 580mL (13%) 810mL (18%)
FEV1/FVC 53% 56%
Post BD FVC 1040mL (21%) –
Post BD FEV1 590 (14%) –
6-min walking test Impossible 490m
mMRC 4 2
CAT 37 20
BFI 80 45
MFIS 71 34
FIM 98 118
LCADL 65 36
BD=bronchodilator, BFI=Brief Fatigue Inventory, CAT=COPD Assessment Test, FEV1= forced
expiratory volume in 1 s, FIM= Functional Independence Measure, FVC= forced vital capacity,
LCADL=London Chest Activity of Daily Living, MFIS=Modiﬁed Fatigue Impact Scale, mMRC=
modiﬁed Medical Research Council, NIPPV=noninvasive intermittent positive pressure ventilator.2. Case report
The patient was diagnosed with acute myeloid leukemia in 1994
at the age of 19 and underwent bone marrow transplantation. As
a sequela of the graft versus host disease after the transplantation,
he exhibited symptoms of dyspnea in 1995 and was diagnosed
with COPD in 1996. The patient regularly underwent medical
treatment, but the dyspnea continued to exacerbate. As the
resting state oxygen saturation level decreased to <90%, long-
term oxygen therapy was commenced in September 2015.
Dyspnea and deterioration of physical activity continued to
worsen. Beginning in June 2016, he was nearly sedentary and
suffered from swallowing difﬁculty, accompanied by frequent
symptoms of aspiration. In November 2016, he was referred to
our department for the evaluation of dysphagia. At that time,
although his manual muscle power was good in both upper and
lower extremities without a focal neurologic deﬁcit, he could not
walk more than 3 to 4m independently. On arterial blood gas
analysis, pCO2 was approximately 70mm Hg. A videoﬂuoro-
scopic swallowing study (VFSS) performed on November 18
revealed delayed oral transit time, impaired laryngeal elevation
and swallowing reﬂex, inadequate upper esophageal sphincter
(UES) opening, and aspiration of liquid. Rehabilitative treatment
of dysphagia was commenced; however, the follow-up VFSS,
performed on November 29 and December 20 of 2016, showed
continued aggravation, despite a medically stable condition and
regular oromotor training. No abnormal ﬁndings were observed
in the brain magnetic resonance imaging or electrodiagnostic
study, which were conducted to identify any other causes of
dysphagia.
The patient was admitted to our department on December 28,
2016, for consideration of NIPPV. The transcutaneous pCO2
monitoring, performed overnight via V-Sign Sensor (SenTec
Digital Blood Gas Monitoring System; Sentec AG, Therwil,
Switzerland), indicated a maximal pCO2 of 72.8mm Hg and a
mean pCO2 of 62.4mmHg. Nocturnal NIPPV, with the mode of
bilevel positive airway pressure, was then applied via a nasal
mask; pCO2 monitoring conducted with the ventilator on
January 6, 2017, showed an improvement, indicating a maximal
pCO2 of 50.8mm Hg and a mean pCO2 of 47mm Hg. After
undergoing NIPPV treatment, the patient showed a remarkable
improvement in physical function. The patient could not even
perform a 6-minute walking test (6MWT) in August and
November 2016; however, on February 28, 2017, he completed
a 490-m walk and SpO2 was measured at 94% after the
examination, without oxygen supply. In examinations, such as
the Brief Fatigue Inventory (BFI), COPD Assessment Test, and
Modiﬁed Fatigue Impact Scale (MFIS), the patient also showed
improvements in COPD symptoms and fatigue-related indica-
tors. These improvements led to enhancement in activities of daily
living (ADL), resulting a remarkable improvement in indices such
as the Functional Independence measure (FIM) and London
Chest Activity of Daily Living (LCADL) test (Table 1).
The patient was readmitted to our department on March 15,
2017. During transcutaneous pCO2 monitoring with nocturnal
NIPPV, the patient showed improvement, with a maximal pCO2
of 37.7mmHg and a mean pCO2 of 35.8mmHg. The follow-up2VFSS showed an improvement, compared with the previous
study; only penetration was observed when swallowing liquids.
During this period, medications related to COPD were not
changed.3. Discussion
The effect of applying NIPPV in COPD patients has been proven.
It corrects acute respiratory acidosis and relieves dyspnea during
acute exacerbation, leading to a lowered rate of ventilator-
associated pneumonia and extended hospital stays that often
result in mortality. Long-term application of NIPPV may also
improve survival rate and quality of life.[4] However, in regards to
physical function, inconsistent results have been reported,
especially in severe stages. In previous studies, an improvement
of exercise tolerance after the application of NIPPV was only
found in mild or moderate COPD. Unlike previous studies, we
found an improvement in exercise tolerance, as measured by the
6MWT, in a severe COPD patient.[5,6] We found both
improvement of physical function and of exercise tolerance after
applying NIPPV; there are many factors that can affect this
dramatic improvement, including the patient’s relatively young
age. Importantly, there has been no previous study showing
dramatic improvement of physical function in a severe COPD
patient solely after NIPPV.
Fatigue is one of the typical symptoms among COPD patients,
which exacerbates as COPD progresses. Abundant evidence
shows that dysfunction of the skeletal muscles in COPD patients
contributes to such fatigue. In the case of lower extremity
muscles, the proportion of type II ﬁbers becomes increased,
resulting in vulnerability to fatigue in the lower extremities. These
ﬁndings are more pronounced in patients with severe COPD.[7]
The patient in this study also had experienced a very severe
COPD state for a long period, during which the lower extremity
muscles had become particularly vulnerable, such that the
distance of walking became gradually shortened. Studies have
shown that the application of NIPPV to patients with severe
COPD elicits improvement in various indices; however, there is
no clear effect on exercise endurance.[5,6] In this case, NIPPV
treatment improvedmuscle fatigue, which wasmeaningful in that
Jung et al. Medicine (2018) 97:43 www.md-journal.comit led to dramatic improvement of the ability to perform the ADL.
The BFI and MFIS (fatigue-related questionnaires) indicated
dramatic recovery after NIPPV treatment, which induced
improvements in both ambulatory function and in the ADL.
This was further manifested by changes in the FIM and LCADL
indices.
A previous study has shown that the overall survival rate and
HRQOL were signiﬁcantly improved among GOLD stage IV
COPD patients to whom long-term NIPPV was applied in
addition to the standard treatment; however, there was no
signiﬁcant difference in the results of the 6MWT.[6] The patient in
this study, unlike in the previous studies, clearly showed
remarkable improvement in his exercise capacity. There are 2
major differences between the patient in this case and the patient
group in the prior study. First, the subjects recruited in the prior
study were clinically stable. In this case report, however, the
patient underwent drastic exacerbation of dyspnea and pulmo-
nary functions during the 6 months preceding NIPPV treatment.
Further, there is an age difference of approximately 20 years
between the group in the prior study (mean age, 62.2 years) and
this case patient (42 years). Considering these differences, NIPPV
treatment may be expected to improve the exercise capacities of a
relatively young patient with a marked deterioration of
symptoms and function, compared with a stable old patient.
According to a recent review article, various mechanisms have
been suggested with respect to the causes of increased dysphagia
in COPD patients.[8] However, no study has been published
showing that the use of NIPPV is related to remarkable
improvements in swallowing function; to our knowledge, this
case report is the ﬁrst to document improvement in dysphagia
after nocturnal NIPPV.4. Conclusion
We observed improvement in the exercise capacity, restored
independence in the ADL, and recovery of dysphagia, when
respiratory support with NIPPV alone was applied to a very3severe COPD patient with hypercapnia. Therefore, NIPPV may
be useful as a treatment option for such patients.Author contributions
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